

C4 Therapeutics partners with Roche to develop cancer-fighting DACs. CCCC eligible for $1B+ in milestones plus royalties. See the details.
You can purchase shares of C4 Therapeutics (NASDAQ:CCCC) through any online brokerage.
Other companies in C4 Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
C4 Therapeutics has a consensus price target of $11.50.
The stock price for C4 Therapeutics (NASDAQ: CCCC) is $3.12 last updated October 23, 2026 at 7:16 AM EDT.
There are no upcoming dividends for C4 Therapeutics.
C4 Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for C4 Therapeutics.
C4 Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing...